Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt N/A
PRAN's Cash to Debt is ranked higher than
60% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. PRAN: N/A )
Ranked among companies with meaningful Cash to Debt only.
PRAN' s Cash to Debt Range Over the Past 10 Years
Min: 16.62  Med: 10000.00 Max: No Debt
Current: N/A
Equity to Asset 0.94
PRAN's Equity to Asset is ranked higher than
92% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PRAN: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
PRAN' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.81 Max: 0.96
Current: 0.94
0.57
0.96
Interest Coverage No Debt
PRAN's Interest Coverage is ranked higher than
90% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRAN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PRAN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 6.19
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -164.63
PRAN's Operating margin (%) is ranked lower than
58% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. PRAN: -164.63 )
Ranked among companies with meaningful Operating margin (%) only.
PRAN' s Operating margin (%) Range Over the Past 10 Years
Min: -3850.92  Med: -1771.25 Max: -152.91
Current: -164.63
-3850.92
-152.91
Net-margin (%) -90.61
PRAN's Net-margin (%) is ranked lower than
54% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. PRAN: -90.61 )
Ranked among companies with meaningful Net-margin (%) only.
PRAN' s Net-margin (%) Range Over the Past 10 Years
Min: -3945.4  Med: -1639.88 Max: -90.62
Current: -90.61
-3945.4
-90.62
ROE (%) -20.78
PRAN's ROE (%) is ranked higher than
58% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. PRAN: -20.78 )
Ranked among companies with meaningful ROE (%) only.
PRAN' s ROE (%) Range Over the Past 10 Years
Min: -175.24  Med: -95.34 Max: -15.33
Current: -20.78
-175.24
-15.33
ROA (%) -19.09
PRAN's ROA (%) is ranked higher than
57% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. PRAN: -19.09 )
Ranked among companies with meaningful ROA (%) only.
PRAN' s ROA (%) Range Over the Past 10 Years
Min: -139.67  Med: -76.22 Max: -14.1
Current: -19.09
-139.67
-14.1
ROC (Joel Greenblatt) (%) -156.36
PRAN's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. PRAN: -156.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRAN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -21719.66  Med: -8341.04 Max: -154.1
Current: -156.36
-21719.66
-154.1
EBITDA Growth (3Y)(%) -20.60
PRAN's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. PRAN: -20.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRAN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.60 Max: 22.9
Current: -20.6
0
22.9
EPS Growth (3Y)(%) -12.60
PRAN's EPS Growth (3Y)(%) is ranked lower than
60% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PRAN: -12.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRAN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -12.60 Max: 71
Current: -12.6
0
71
» PRAN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with PRAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.09
PRAN's P/B is ranked higher than
86% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. PRAN: 1.09 )
Ranked among companies with meaningful P/B only.
PRAN' s P/B Range Over the Past 10 Years
Min: 1  Med: 3.17 Max: 31.75
Current: 1.09
1
31.75
P/S 5.25
PRAN's P/S is ranked higher than
66% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. PRAN: 5.25 )
Ranked among companies with meaningful P/S only.
PRAN' s P/S Range Over the Past 10 Years
Min: 5.25  Med: 20.00 Max: 127
Current: 5.25
5.25
127
Days Sales Outstanding 366.24
PRAN's Days Sales Outstanding is ranked lower than
95% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. PRAN: 366.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.85  Med: 70.17 Max: 366.29
Current: 366.24
0.85
366.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.83
PRAN's Price/Net Cash is ranked higher than
95% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 18.00 vs. PRAN: 0.83 )
Ranked among companies with meaningful Price/Net Cash only.
PRAN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.07  Med: 8.33 Max: 149
Current: 0.83
1.07
149
Price/Net Current Asset Value 0.67
PRAN's Price/Net Current Asset Value is ranked higher than
97% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. PRAN: 0.67 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PRAN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 7.50 Max: 149
Current: 0.67
1.07
149
Price/Tangible Book 0.77
PRAN's Price/Tangible Book is ranked higher than
94% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. PRAN: 0.77 )
Ranked among companies with meaningful Price/Tangible Book only.
PRAN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.07  Med: 7.00 Max: 149
Current: 0.77
1.07
149
Price/Median PS Value 0.04
PRAN's Price/Median PS Value is ranked higher than
99% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. PRAN: 0.04 )
Ranked among companies with meaningful Price/Median PS Value only.
PRAN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 0.94 Max: 10.75
Current: 0.04
0.55
10.75
Earnings Yield (Greenblatt) (%) -12.34
PRAN's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. PRAN: -12.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRAN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.45  Med: 3142.30 Max: 3142.3
Current: -12.34
-13.45
3142.3

More Statistics

Revenue(Mil) $5
EPS $ -0.09
Beta0.31
Short Percentage of Float0.55%
52-Week Range $0.45 - 1.85
Shares Outstanding(Mil)53.39

Analyst Estimate

Jun16 Jun17
Revenue(Mil)
EPS($) -0.03 -0.03
EPS without NRI($) -0.03 -0.03

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PBT.Australia, PBNA.Germany, PRNAF.USA,
Prana Biotechnology Ltd was incorporated on November 11, 1997. The Company is a development stage company at an early stage in the development of its pharmaceutical products. The Company's activities include research into Alzheimer 's disease and other age-related degenerative disorders. Its compound PBT2, is manufactured by Dr. Reddys based in Hyderabad, India. It competes with pharmaceutical companies, biotechnoloy firms, universities and research institutions. The Company is subject to governmental laws and regulations.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK